Coronavirus | Biocon’s COVID-19 drug tested on too few patients to reliably conclude on benefits, say experts
Biocon Ltd’s psoriasis drug, Itolizumab, re-purposed for COVID-19 and headlined as “breakthrough drug” for treating the moderately sick and the…